Benzenesulfonic acids and derivatives
Medchemexpress LLC 5-Sulfosalicylic acid (dihydrate) | 5965-83-3 | 99.9% | 50 G
5-Sulfosalicylic acid dihydrate is a sulfonated salicylic acid derivative that demonstrates effectiveness against the breast cancer cell line MCF-7 with reduced toxicity and possesses antioxidant activities.
- Effective against breast cancer cell line MCF-7
- Reduced toxicity
- Possesses antioxidant activities
- Reduces cell viability in MCF-7 cells at 0.5-4 mM concentrations
- Leads to 63.3% viability in MCF-7 cells at 1 mM and 70.4% in HUVEC control cells after 24 hours
Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 25 MG
I-138 is an orally active, reversible inhibitor of USP1-UAF1, with an IC50 of 4.1 nM and a Ki of 5.4 nM. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells. It is structurally related to ML323.
- Reversible inhibitor of USP1-UAF1
- Induces monoubiquitination of FANCD2 and PCNA in cells
- Eliminates USP1 autocleavage in cells
- Inhibits MDA-MB-436 cell viability
- Shows modest antitumor activity in mice bearing MDA-MB-436 tumors
- Can be combined with Niraparib for BRCA1/2 mutant tumor inhibition
Medchemexpress LLC 5-Sulfosalicylic acid | 97-05-2 | 98.7% | 1 ML
5-Sulfosalicylic acid is a sulfonated salicylic acid derivative that has demonstrated effectiveness against breast cancer cell lines with reduced toxicity and exhibits antioxidant activities. It has been shown to reduce the viability of MCF-7 cells in vitro.
- Sulfonated salicylic acid derivative
- Effective against breast cancer cell lines
- Reduced toxicity
- Exhibits antioxidant activities
- Reduces viability of MCF-7 cells
Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 50 MG
I-138 is an orally active, reversible inhibitor of USP1-UAF1 (IC50: 4.1 nM; Ki: 5.4 nM), structurally related to ML323. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells.
- Eliminates USP1 self-lysis in HAP-1 USP1 WT and knockout cells
- Induces monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells
- Dose-dependently inhibits MDA-MB-436 cell viability
- Results in USP1 inhibition and modest antitumor activity in mice bearing MDA-MB-436 tumors
- Benefits BRCA1/2 mutant tumor inhibition when combined with Niraparib
Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 1 ML
I-138 is an orally active, reversible inhibitor of USP1-UAF1, with an IC50 of 4.1 nM and Ki of 5.4 nM. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells. It is intended for research use only.
- Eliminates USP1 self-lysis in HAP-1 USP1 WT and knockout cells
- Induces monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells
- Dose-dependently inhibits MDA-MB-436 cell viability
- Results in USP1 inhibition and modest antitumor activity in mice bearing MDA-MB-436 tumors
- Benefits BRCA1/2 mutant tumor inhibition in vivo when combined with Niraparib
Medchemexpress LLC 5-sulfosalicylic acid (dihydrate) | 5965-83-3 | 99.9% | 250 G
5-Sulfosalicylic acid dihydrate is a sulfonated salicylic acid derivative. It is effective against the breast cancer cell line, MCF-7, with less toxicity and also exhibits antioxidant activities.
- Effective against the breast cancer cell line, MCF-7, with less toxicity
- Exhibits antioxidant activities
- Reduces viability of MCF-7 cells
Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 100 MG
I-138 is an orally active, reversible inhibitor of USP1-UAF1. It induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage. This compound is structurally related to ML323.
- Orally active and reversible inhibitor of USP1-UAF1
- Induces monoubiquitination of FANCD2 and PCNA in cells
- Eliminates USP1 autocleavage in cells
- Shows dose-dependent inhibition of MDA-MB-436 cell viability
- Exhibits modest antitumor activity in mice bearing MDA-MB-436 tumors
- Can be combined with Niraparib for BRCA1/2 mutant tumor inhibition in vivo
Medchemexpress LLC 5-Sulfosalicylic acid (dihydrate) | 5965-83-3 | 99.9% | 25 G
5-Sulfosalicylic acid dihydrate is a sulfonated salicylic acid derivative that is effective against the breast cancer cell line MCF-7 with less toxicity. It also possesses antioxidant activities and is intended for research use only.
- Effective against breast cancer cell line MCF-7
- Exhibits less toxicity
- Possesses antioxidant activities
- Reduces viability of MCF-7 cells
Selleck Chemical LLC I-138-E1479-1G
I-138 is an orally active potent reversible inhibitor of USP1-UAF1 with IC50 0f 4 1 nM I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells
Selleck Chemical LLC I-138-E1479-25MG
I-138 is an orally active potent reversible inhibitor of USP1-UAF1 with IC50 0f 4 1 nM I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells
Selleck Chemical LLC I-138-E1479-5MG
I-138 is an orally active potent reversible inhibitor of USP1-UAF1 with IC50 0f 4 1 nM I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells
Selleck Chemical LLC I-138-E1479-100MG
I-138 is an orally active potent reversible inhibitor of USP1-UAF1 with IC50 0f 4 1 nM I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells
Medchemexpress LLC 5-Sulfosalicylic acid dihydrate | 5965-83-3 | 99.9% | 10 MM 1 ML
5-Sulfosalicylic acid dihydrate is a sulfonated salicylic acid derivative. It is effective against the breast cancer cell line, MCF-7, with less toxicity and possesses antioxidant activities.
- It is a sulfonated salicylic acid derivative.
- It demonstrates effectiveness against the breast cancer cell line, MCF-7, with reduced toxicity.
- It possesses antioxidant activities.
- It can reduce the viability of MCF-7 cells in vitro.
- It is for research use only.
Medchemexpress LLC 5-Sulfosalicylic acid | 97-05-2 | 98.7% | 100 MG
5-Sulfosalicylic acid is a sulfonated salicylic acid derivative that demonstrates effectiveness against breast cancer cell lines with reduced toxicity. Additionally, it exhibits antioxidant activities.
- Effective against breast cancer cell lines with less toxicity.
- Possesses antioxidant activities.
Medchemexpress LLC I-138 | 2098211-50-6 | C26H23F3N6O | 1 MG
I-138 is an orally active, reversible inhibitor of USP1-UAF1 (IC50: 4.1 nM; Ki: 5.4 nM), structurally related to ML323 (HY-17543). I-138 induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells.
- Orally active and reversible inhibitor of USP1-UAF1.
- Potent inhibitory activity against USP1-UAF1 (IC50: 4.1 nM; Ki: 5.4 nM).
- Induces monoubiquitination of FANCD2 and PCNA in cells.
- Eliminates USP1 autocleavage in cells.
- Demonstrates modest antitumor activity in mice bearing MDA-MB-436 tumors.
- Shows enhanced inhibition of BRCA1/2 mutant tumors in vivo when combined with the PARP inhibitor Niraparib.
- 1
- 2